07:22 AM EDT, 06/26/2025 (MT Newswires) -- Pfizer ( PFE ) said Thursday that its phase 3 trial met the primary endpoint with Hympavzi reducing annualized bleed rates by 93% in patients with hemophilia A or B with inhibitors compared to prior on-demand treatment.

In the 48-patient study, the annualized bleeding rate dropped to 1.39 with Hympavzi from 19.78 on bypassing agents, the company said.

The once-weekly subcutaneous therapy also met all bleeding-related secondary endpoints, including a reduction in spontaneous and joint bleeds, according to Pfizer ( PFE ).